New Staph-Fighting skin regimen shows promise in High-Risk community
NCT ID NCT06210594
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a combination of topical antibiotics and antiseptic washes could reduce staph bacteria on the skin of Native American adults living on or near tribal lands. Participants were at high risk for staph infections due to diabetes, obesity, or recent infections. The trial compared the biomedical regimen plus education and household supplies to education and supplies alone, measuring staph carriage and infection rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mupirocin (Bactroban) + Nozin + chlorhexidine gluconate (Hibiclens)
- What this could lead to
- If successful, this approach could reduce staph infections in high-risk communities by lowering the amount of staph bacteria on the skin.
- What could go wrong
- This is a small, completed Phase 4 trial with only 78 participants, so results may not apply to broader populations. The regimen requires ongoing use, and long-term adherence may be challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Whiteriver Center for Indigenous Health
Whiteriver, Arizona, 85941, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.